A high-throughput screening campaign to discover small molecule leads for the treatment of bone disorders concluded with the discovery of a compound with a 2-aminopyrimidine template that targeted the Wnt beta-catenin cellular messaging system. Hit-to-lead in vitro optimization for target activity and molecular properties led to the discovery of (1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine (5, WAY-262611). Compound 5 has excellent pharmacokinetic properties and showed a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm9014197 | DOI Listing |
Publication Analysis
Top Keywords
bone formation
8
formation rate
8
1-4-naphthalen-2-ylpyrimidin-2-ylpiperidin-4-ylmethanamine wingless
4
wingless beta-catenin
4
beta-catenin agonist
4
agonist increases
4
increases bone
4
rate high-throughput
4
high-throughput screening
4
screening campaign
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!